{"id":"aslan003","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2263632","moleculeType":"Small molecule","molecularWeight":"356.33"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, ASLAN003 prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.","oneSentence":"ASLAN003 is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:22.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05865041","phase":"PHASE2","title":"Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants","status":"UNKNOWN","sponsor":"ASLAN Pharmaceuticals","startDate":"2023-04-14","conditions":"Alopecia Areata","enrollment":60},{"nctId":"NCT03451084","phase":"PHASE2","title":"A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2018-01-05","conditions":"Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT01992367","phase":"PHASE1","title":"Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":61},{"nctId":"NCT02342652","phase":"PHASE1","title":"A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2014-10","conditions":"Healthy Elderly Subjects (Age ≥55 Years)","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LAS186323"],"phase":"phase_2","status":"active","brandName":"ASLAN003","genericName":"ASLAN003","companyName":"ASLAN Pharmaceuticals","companyId":"aslan-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASLAN003 is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}